Loading clinical trials...

Laser Ablation in Stereotactic Neurosurgery (LAISE): NeuroBlate® Retrospective Registry | Clinical Trials | Clareo Health

COMPLETED

Laser Ablation in Stereotactic Neurosurgery (LAISE): NeuroBlate® Retrospective Registry

Laser Ablation in Stereotactic Neurosurgery

NCT02389855•Monteris Medical

View on ClinicalTrials.gov

Summary

The NeuroBlate® System (NBS), is a minimally invasive robotic laser thermotherapy tool. It employs a pulsed surgical laser to deliver targeted energy to abnormal brain tissue caused by tumors and lesions. Since receiving FDA clearance in April 2013, the NBS has been used in nearly 300 procedures conducted at approximately 20 leading institutions across the United States. This post-market, multi-center retrospective study is designed to collect long-term follow-up data on patients who were treated previously with NBS.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patient was previously treated with NBS
•Patient is willing and able to provide informed consent and authorization for release of personal health information or IRB waiver is granted to collect study information without patient consent

Locations (9)

Yale University

New Haven, Connecticut, United States

Kansas University Medical Center

Kansas City, Kansas, United States

St. Luke's Hospital

Kansas City, Missouri, United States

Washington University in St. Louis

St Louis, Missouri, United States

Wake Forest

Salem, North Carolina, United States

University Hospitals Cleveland Medical Center

Cleveland, Ohio, United States

Cleveland Clinic

Cleveland, Ohio, United States

Thomas Jefferson University

Philadelphia, Pennsylvania, United States

The University of Texas MD Anderson Cancer Center

Houston, Texas, United States

Key Dates

Start Date

February 1, 2015

Primary Completion Date

August 1, 2016

Completion Date

August 1, 2016

Last Updated

April 12, 2024

Enrollment

144

ACTUAL participants

Conditions

Primary Brain Tumor

Interventions

NeuroBlate® System Therapy

PROCEDURE

Assessment of Eloquent Function in Brain Tumor Patients

NCT01535430

Primary Brain TumorMetastatic Brain Tumor

View study

ACTIVE_NOT_RECRUITINGEARLY_PHASE1

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

NCT05634707

Primary Brain TumorBrain Tumor, Recurrent

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 12, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Laser Ablation in Stereotactic Neurosurgery (LAISE): NeuroBlate® Retrospective Registry

Inclusion Criteria

Assessment of Eloquent Function in Brain Tumor Patients

Evaluation of Fluoxetine and Cytotoxic Lysosomal Stress in Glioma (FLIRT)

Pharmacoscopy for Patients With Refractory Primary Brain Tumors

Safety and Imaging Study of GC1008 in Glioma

Impact of the Development of Pediatric Palliative Care

CBT for Insomnia in Primary Brain Tumor Patients